title: [Novel monoclonal antibodies for the treatment of malignant lymphomas].
authors: Dai
authors: D
authors: Maruyama
mesh_terms: D000074323:Alemtuzumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000912:Antibodies, Neoplasm / Q000008:administration & dosage*; D015703:Antigens, CD / Q000276:immunology; D018951:Antigens, CD20 / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000079963:Brentuximab Vedotin; D000074301:CD52 Antigen; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D015195:Drug Design; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage*; D000080045:Inotuzumab Ozogamicin; D017730:Ki-1 Antigen / Q000276:immunology; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008224:Lymphoma, Follicular / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D051379:Mice; D058990:Molecular Targeted Therapy / Q000639:trends*; D054398:Receptors, CCR4 / Q000276:immunology; D051918:Sialic Acid Binding Ig-like Lectin 2 / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D018951:Antigens, CD20; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; C515354:CCR4 protein, human; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D054398:Receptors, CCR4; D051918:Sialic Acid Binding Ig-like Lectin 2; D000074323:Alemtuzumab; D000079963:Brentuximab Vedotin; C527517:ofatumumab; C543332:obinutuzumab; D000080045:Inotuzumab Ozogamicin; C549035:mogamulizumab